


FIG. 1






FIG. 3






FIG. 3 continued

b*in vitro*:

HEK293-DC-SIGN cells

DENV-1 E216A
passage 10DENV-1 WT
passage 10DENV-2 E217A
passage 10DENV-2 WT
passage 10**c***ex vivo*:

infected AG129 mice day 3



DENV-1 E216A
ex vivoDENV-1 E216A
+DENV-2 E217A
ex vivoDENV-2 E217A
ex vivoDENV-1 E216A
+DENV-2 E217A
ex vivo

FIG. 4




FIG. 4 continued




FIG. 5





FIG. 6






FIG. 8




FIG. 8 continued






FIG. 9



- △ no serum
- day5 post infection with DENV-2 WT
- day5 post challenge with DENV-2 WT

FIG. 9 continued




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG.14




FIG. 15




FIG. 16




FIG. 17




FIG. 18

